节点文献
复方泽桑汤联合胸腺肽 治疗系统性硬皮病的临床疗效观察
Effect of Zesang Polypharmacy Combined with Thymic Peptide on Treating Systemic Scleroderma
【摘要】 目的回顾性分析复方泽桑汤联合胸腺肽治疗系统性硬皮病66例的临床疗效。方法评估复方泽桑汤联合胸腺肽治疗系统性硬皮病66例半年后的疗效。结果痊愈18例(27.3%),显效24例(36.4%),好转20例(30.3%),无效4例(6.1%),有效率为63.64%(42/66)。结论复方泽桑汤联合胸腺肽治疗系统性硬皮病疗效显著。
【Abstract】 Objective To investigate the effect of Zesang polypharmacy combined with thymic peptide in treating systemic scleroderma(SSc).Methods 66 patients with SSc were treated with Zesang polypharmacy and thymic peptide for half a year,and than the score was measured to evaluate the treatment effect.Results The effective rate of combined treatment was 63.64%(42/66).Conclusion Zesang polypharmacy combined with thymic peptide seems to be effective in treating systemic scleroderma.
- 【文献出处】 中国中西医结合皮肤性病学杂志 ,Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine , 编辑部邮箱 ,2012年02期
- 【分类号】R593.25
- 【被引频次】1
- 【下载频次】85